Puig L, Tsai TF, Bhutani T, et al. - Researchers performed evaluation of safety in moderate‐to‐severe psoriasis patients with latent tuberculosis infection (LTBI) treated with guselkumab (IL‐23 inhibitor) and LTBI treatment. In the VOYAGE 1 and 2 studies, 130 eligible patients were randomized to guselkumab, placebo, or adalimumab (TNF inhibitor) at baseline. Placebo→guselkumab crossover occurred at week (wk)16 and adalimumab→guselkumab at wk52 (VOYAGE 1), or at wk28 or later (VOYAGE 2). Outcomes revealed no active TB, including reactivation of LTBI, in any of cases with or without LTBI treated with guselkumab through up to 2 years. Across all treatment groups, reactivation of LTBI was effectively checked by LTBI treatment. Patients receiving LTBI medications generally well‐tolerated long‐term treatment with guselkumab through up to 2 years.